Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Research & Development (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Research & Development for 7 consecutive years, with $15.6 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 59.83% to $15.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $109.2 million through Dec 2025, down 35.53% year-over-year, with the annual reading at $109.2 million for FY2025, 35.53% down from the prior year.
  • Research & Development for Q4 2025 was $15.6 million at Pliant Therapeutics, down from $17.9 million in the prior quarter.
  • The five-year high for Research & Development was $47.8 million in Q3 2024, with the low at $15.6 million in Q4 2025.
  • Average Research & Development over 5 years is $29.0 million, with a median of $27.8 million recorded in 2022.
  • The sharpest move saw Research & Development soared 47.67% in 2024, then plummeted 62.44% in 2025.
  • Over 5 years, Research & Development stood at $18.8 million in 2021, then surged by 33.93% to $25.1 million in 2022, then skyrocketed by 32.13% to $33.2 million in 2023, then rose by 16.91% to $38.8 million in 2024, then tumbled by 59.83% to $15.6 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $15.6 million, $17.9 million, and $32.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.